This Investment will add a differentiated ophthalmic platform, targeting an estimated 3 million annual U.S. cataract surgeries with long-acting, “dropless” pain and inflammation treatmentTEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments for ophthalmic ...

NASDAQ: ZYXI Investor Presentation April 2025 Forward Looking Statement This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated e ...

Collegium Pharmaceutical (COLL) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Hi. Good afternoon. Welcome to day two of the Jefferies Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the great pleasure of having Collegium Pharmaceuticals here to give us a presentation. We have CEO Vikram Karnani here. So welcome Vikram. Speaker1 Thank you Dennis. I'd like to remind everyone that during this presentation I will be making forward looking statements. Please refer to ...

PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal. GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchici ...

Pacira BioSciences Inc (PCRX) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Hi, good morning. Welcome to the Jefferies Healthcare Conference in New York, day one. My name is Dennis Singh, biotech analyst here at Jefferies. I have the pleasure of having Paseer Biosciences CEO, Frank Lee, here with us. Welcome. Frank, maybe to kind of kick things off, just give a brief overview of the company for those who aren't familiar. Just talk about the business and, you know, how things have evolved over the last ...

Core Insights - The article emphasizes the importance of bridging scientific expertise with financial strategy in the healthcare sector to uncover hidden value and assess risks accurately [1]. Group 1: Company Overview - ELAM1 empowers financial professionals and investors by providing scientific and clinical expertise necessary for navigating the complexities of the healthcare sector [1]. Group 2: Services Offered - The company assists clients in making informed investment decisions in life sciences by leveraging cutting-edge science [1].

Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and OlderNASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients. The analysis evaluated the safety and efficacy of Caldolor for the management of pain and fever in patients 60 years of age and older. It marks an important ...

Pacira BioSciences Inc (PCRX) 2025 Conference May 21, 2025 08:30 AM ET Speaker0 Welcome back everyone to the twenty twenty five RBC Global Healthcare Conference. My name is Greg Renza, one of the biotech analysts, and we're pleased to be joined now by Pacira Biosciences. Joining us from the company is the Chief Executive Officer, Frank Lee. Frank, great to see you. Thanks for being here. Speaker1 Good to see you, Greg. Yeah. Happy to be here. Speaker0 Great. Great. Well, always a lot going on in the externa ...

First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces ...

Collegium Pharmaceutical (COLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Ian Karp - Head of IRVikram Karnani - President & CEOScott Dreyer - Executive VP & Chief Commercial OfficerColleen Tupper - Executive VP & CFOLes Sulewski - VP - Biotech Equity Research Conference Call Participants Serge Belanger - Senior AnalystDavid Amsellem - Sr. Research Analyst Operator and welcome to the Collegium Pharmaceutical First Quarter twenty twenty five Earnings Conference Call. At this time, al ...